5news.Canadian news, all in one place

BREAKING

› Novo Resources Releases Updated Corporate Presentation › Work begins to build public housing project near Toronto’s Trinity Bellwoods Park › Rainbow Valley Bridge work wrapping up on Whitemud Drive › News of the day: Auto tariff threats, TFSA as education fund, Unifor-GM labour deal, BDC expands into defence sector, settlement negotiations and more › Co-accused in murder of 29-year-old Chelsea Davidenas sentenced to life in prison following guilty plea › 1 in 3 Ontario children are living in food-insecure homes: Breakfast Club of Canada › Meet Howard Lutnick: Is this the man who killed the trade talks?› U.S. seeks to make Iran an ‘economic outcast’ with new sanctions, pressure › Calian completes acquisition of Galaxy Broadband › ‘Pretty heavy’: Work on legacy mural begins in Vancouver’s Downtown Eastside › Novo Resources Releases Updated Corporate Presentation › Work begins to build public housing project near Toronto’s Trinity Bellwoods Park › Rainbow Valley Bridge work wrapping up on Whitemud Drive › News of the day: Auto tariff threats, TFSA as education fund, Unifor-GM labour deal, BDC expands into defence sector, settlement negotiations and more › Co-accused in murder of 29-year-old Chelsea Davidenas sentenced to life in prison following guilty plea › 1 in 3 Ontario children are living in food-insecure homes: Breakfast Club of Canada › Meet Howard Lutnick: Is this the man who killed the trade talks?› U.S. seeks to make Iran an ‘economic outcast’ with new sanctions, pressure › Calian completes acquisition of Galaxy Broadband › ‘Pretty heavy’: Work on legacy mural begins in Vancouver’s Downtown Eastside

Business

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

Financial Post · August 24, 2026 at 4:35 p.m.

VAUGHAN, Ontario -- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results.

Read More

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

More from Financial Post

Novo Resources Releases Updated Corporate Presentation

Financial Post · 14 min ago

News of the day: Auto tariff threats, TFSA as education fund, Unifor-GM labour deal, BDC expands into defence sector, settlement negotiations and more

Financial Post · 22 min ago

Calian completes acquisition of Galaxy Broadband

Financial Post · 36 min ago

Philips prices EU green bond for EUR 650M

Financial Post · 41 min ago

More in Business

Novo Resources Releases Updated Corporate Presentation

Financial Post · 14 min ago

News of the day: Auto tariff threats, TFSA as education fund, Unifor-GM labour deal, BDC expands into defence sector, settlement negotiations and more

Financial Post · 22 min ago

Calian completes acquisition of Galaxy Broadband

Financial Post · 36 min ago

Philips prices EU green bond for EUR 650M

Financial Post · 41 min ago

Hamilton ETFs Announces August 2026 Monthly & Upcoming Semi-Monthly Cash Distributions

Financial Post · 43 min ago

Slate Grocery REIT Announces Distribution for the Month of August 2026

Financial Post · 44 min ago